Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer

Couper, Graeme; McAteer, Dympna; Wallis, F.; Norton, M. Y.; Welch, Andrew; Nicolson, Marianne; Park, K. G. M.

doi:10.1046/j.1365-2168.1998.00963.x

Cited by 89 publications

(28 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are few published data on the use of PET in assessing response to neoadjuvant treatment. In a study of 14 patients undergoing chemotherapy for oesophageal cancer 154 PET was no better than CT at determining response to treatment. With PET there is limited spatial resolution and possible attenuation of deep lesions, making the detection of small tumour lesions unreliable 150,152 .…”

Section: Role Of Positron Emission Tomographymentioning

confidence: 94%

Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer

Geh

Crellin²,

Glynne‐Jones

2001

British Journal of Surgery

191

138

View full text Add to dashboard Cite

show abstract

Section: Role Of Positron Emission Tomographymentioning

confidence: 94%

Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer

Geh

Crellin²,

Glynne‐Jones

2001

British Journal of Surgery

191

138

View full text Add to dashboard Cite

show abstract

“…15,[18][19][20][21] The potential of FDG-PET to detect the response to neoadjuvant therapy in a series of patients with upper gastrointestinal (GI) malignancy was first reported in 1998. 22 Subsequent reports on the ability of FDG-PET to identify pathological responders have reached conflicting conclusions. [23][24][25][26][27][28][29][30][31] However, for patients with SCC of the esophagus there appears to be a correlation between a significant reduction in the FDG-PET uptake in the primary lesion and a significant pathological reduction in the disease.…”

Section: Introductionmentioning

confidence: 99%

Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus

et al. 2008

View full text Add to dashboard Cite

Our aim was to determine if fluorodeoxyglucose positron emission tomography (FDG-PET) could be correlated with a pathological response in patients with esophageal adenocarcinoma receiving neoadjuvant chemotherapy and/or chemoradiation therapy. Patients with resectable, histologically proven adenocarcinoma of the esophagus were entered in the study. Preoperative chemotherapy comprised two cycles of cisplatin and 5-fluorouracil. Radiation therapy commenced with the second cycle on day 22. FDG-PET images were obtained pre-treatment and on completion of intended neo-adjuvant treatment. Quantification was achieved by the calculation of both standardized uptake values (SUV) and tumor/liver ratios (TLR). Evidence of histopathological response was identified according to the Mandard tumor regression scoring system. There were 45 patients, 22 receiving neoadjuvant chemotherapy and 23 chemoradiation therapy. Forty patients underwent surgical resection. Seven patients (16%) had a histopathological response. The mean percentage change in SUV in the histological responders group was -56.8% (SD 29) and in the non-responders -27.8% (SD 32.1) (P = 0.035). The mean percentage change in TLR was -49.1% (SD 44.8) in the responders and in the non-responders -27.3% (SD 31.3) (P = 0.128). There was no difference between the two methods of assessment, however there was less variation with SUV. There was no correlation between the FDG-PET response and the histopathological response. Presently an FDG-PET scan performed 3-6 weeks after neoadjuvant therapy for adenocarcinoma of the esophagus should not be used as a marker of the potential result of the treatment. The optimal timing of a second FDG-PET remains unclear.

show abstract

“…The 19 F NMR technique with 3‐deoxy‐3‐fluoro‐ D ‐glucose as molecular probe is used in studies of metabolism of sugars 29–31 in muscles, the liver, and eyes. Positron emission tomography (PET) with [ 18 F]‐2‐deoxy‐2‐fluoro‐ D ‐glucose is widely utilized in studies on cancer cells 32, in detection of cancer 33–38, its diagnosis 39–46, therapy planning 47, predicting the prognoses 48–50, and monitoring effects of treatment 51–57 in various types of cancers.…”

Section: Introductionmentioning

confidence: 99%

When, in the context of drug design, can a fluorine atom successfully substitute a hydroxyl group?

Hoffmann

Rychlewski

2002

Int J of Quantum Chemistry

View full text Add to dashboard Cite

ABSTRACT:In this article, we deal with the question of whether a fluorine atom can substitute a hydroxyl group in such a way that will lead to a compound showing a desired biologic activity, that is, a potential new drug. It is obvious that a fluorine atom differs from a hydroxyl group, as it cannot donate hydrogen bonds. However, it can accept them. Moreover, both fluorine and oxygen are of similar size and are the most electronegative elements. Therefore, a fluorine atom is thought to be a good substitute for a hydroxyl group. However, it was shown that for conformationally labile aliphatic compounds a replacement of a hydroxyl by a fluorine increases conformational diversity, so the fluorinecontaining aliphatic molecules are present in equilibrium at room temperature as a mixture of several different conformers. In contrast, for cyclic compounds the substitution of an OH group by an F atom does not much change shape and electrostatic potential around corresponding conformers. Moreover, these compounds are present in equilibrium at room temperature in aqueous solution as a mixture of the same most favored structures.

show abstract

Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer

Abstract: Changes in tumour FDG uptake were seen in all tumours after chemotherapy. FDG-PET may have a role to play in the assessment of patients with upper gastrointestinal malignancy receiving chemotherapy.

Cited by 89 publications

References 22 publications

Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer

Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer

Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus

When, in the context of drug design, can a fluorine atom successfully substitute a hydroxyl group?

Contact Info

Product

Resources

About